Formats
  1. Journal Article (67213)
  2. Meeting Abstract (33961)
  3. Book Section (5131)
  4. Review (3840)
  5. Editorial (2231)
  6. Conference Paper (1529)
  7. Guidelines (679)
  8. Correspondence (676)
  9. Research Letter (563)
  10. Book Whole (346)
  11. Miscellaneous (344)
Groups
  1. Department of Medicine (39418)
  2. GSK Faculty (22614)
  3. Solid Tumor Oncology Division (22235)
  4. Surgery (21388)
  5. Survivorship Research (15885)
  6. Sloan Kettering Institute Faculty (15703)

More Groups

People
  1. Marc Ladanyi (1332)
  2. Robert Motzer (1247)
  3. Victor Reuter (1229)
  4. Howard Scher (1130)
  5. Sergio Giralt (1065)
  6. Murray Brennan (1059)

More People

Years
  1. 2026 (7)
  2. 2025 (2818)
  3. 2024 (5600)
  4. 2023 (5809)
  5. 2022 (6169)
  6. 2021 (5720)

More Years

Publications
  1. Journal of Clinical Oncology (8683)
  2. Blood (5169)
  3. Cancer Research (2703)
  4. International Journal of Radiation Oncology, Biology, Physics (2619)
  5. Laboratory Investigation (1890)
  6. Modern Pathology (1817)

More Publications

Publishers
  1. Elsevier Inc. (13940)
  2. American Society of Clinical Oncology (9275)
  3. Springer (7225)
  4. Nature Publishing Group (6436)
  5. American Association for Cancer Research (6026)
  6. American Society of Hematology (5550)

More Publishers

Results (116513)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
    Meeting Abstract

    Cohen, E.; Uppaluri, R.; Lee, N.; Westra, W.; Haddad, R.; Temam, S.; Le Tourneau, C.; Chernock, R.; Safina, S.; Tao, Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    de Braud, F.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B.; Huang, X.; Osborne, S.; Doebele, R. C.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
    Meeting Abstract

    Friedlander, M. L.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients
    Meeting Abstract

    Galon, J.; Hermitte, F.; Mlecnik, B.; Marliot, F.; Bifulco, C.; Lugli, A.; Nagtegaal, I.; Hartmann, A.; van den Eynde, M.; Roehrl, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Asparagine ethylenediamines as anti-malarial plasmodium-selective proteasome inhibitors
    Meeting Abstract

    Zhan, W.; Visone, J.; Harris, J.; Ouellette, T.; Wang, R.; Zang, H.; Singh, P.; Ginn, J.; Sukenick, G.; Wong, T. T.; more...
    American Journal of Tropical Medicine and Hygiene (2019)

    Fulltext@MSK | Save
  • Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Chan, S. L.; Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H. J.; Kim, S.; Lin, Z. Z.; Youkstetter, J.; Sen, S.; Cheng, A. L.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Stem cell-driven lymphatic remodeling coordinates tissue regeneration
    Journal Article

    Gur-Cohen, S.; Yang, H.; Baksh, S. C.; Miao, Y.; Levorse, J.; Kataru, R. P.; Liu, X.; de la Cruz-Racelis, J.; Mehrara, B. J.; Fuchs, E.
    Science (2019)

    Fulltext@MSK | Save
  • Niraparib in patients with newly diagnosed advanced ovarian cancer
    Journal Article

    Gonzalez-Martin, A.; Pothuri, B.; Vergote, I.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
    Journal Article

    Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K. N.; Ben-Baruch, N. E.; Werner, T. L.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Paz-Ares, L.; Caro, R. B.; Zurawski, B.; Kim, S. W.; Costa, E. C.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save